Page results
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
This page is for patients who have been referred on a suspected cancer pathway.
-
At UCLH we run seasonal COVID-19 vaccination clinics from our Hospital Hub within UCH. Vaccinations are available to members of the eligible public as well as UCLH patients.
-
Short videos on managing cancer pain, cancer-related fatigue and improving sleep
-
Our Getting Ready for Transition (GReaT) to secondary school parent information session will run on Wednesday 29 January 2025.
-
This page offers advice to patients who are feeling sick.
-
Bed availability is a “significant” factor in determining whether or not a patient is admitted to a critical care bed after surgery, questioning whether some are getting the care they need, a new study from researchers at UCL and UCLH has found for the first time.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
This page is for patients with obesity who are waiting for scheduled surgery.
-
We’re proud that UCLH is ranked number one of all acute teaching trusts in new national league tables published today.
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology